Antigenic comparison of the neuraminidases from recent influenza A vaccine viruses and 2019–2020 circulating strains

[1]  H. van Bakel,et al.  Novel Epitopes of the Influenza Virus N1 Neuraminidase Targeted by Human Monoclonal Antibodies , 2022, Journal of virology.

[2]  R. Daniels,et al.  Balancing the influenza neuraminidase and hemagglutinin responses by exchanging the vaccine virus backbone , 2020, bioRxiv.

[3]  Hao Wang,et al.  N-Linked Glycan Sites on the Influenza A Virus Neuraminidase Head Domain Are Required for Efficient Viral Incorporation and Replication , 2020, Journal of Virology.

[4]  A. Pekosz,et al.  Neuraminidase antigenic drift of H3N2 clade 3c.2a viruses alters virus replication, enzymatic activity and inhibitory antibody binding , 2020, PLoS pathogens.

[5]  Manish M Patel,et al.  Spread of antigenically drifted influenza A(H3N2) viruses and vaccine effectiveness in the United States during the 2018-2019 season. , 2019, The Journal of infectious diseases.

[6]  I. Wilson,et al.  Structural Basis of Protection against H7N9 Influenza Virus by Human Anti-N9 Neuraminidase Antibodies. , 2019, Cell host & microbe.

[7]  D. Dou,et al.  Structural restrictions for influenza neuraminidase activity promote adaptation and diversification , 2019, Nature Microbiology.

[8]  Yvette N. Lamb.  Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax® Tetra/Flucelvax Quadrivalent®): A Review in the Prevention of Influenza , 2019, Drugs.

[9]  E. Montomoli,et al.  Challenges in the development of egg-independent vaccines for influenza , 2019, Expert review of vaccines.

[10]  M. Eichelberger,et al.  The neuraminidase of A(H3N2) influenza viruses circulating since 2016 is antigenically distinct from the A/Hong Kong/4801/2014 vaccine strain , 2019, Nature Microbiology.

[11]  M. Eichelberger,et al.  Antigenic Drift of the Influenza A(H1N1)pdm09 Virus Neuraminidase Results in Reduced Effectiveness of A/California/7/2009 (H1N1pdm09)-Specific Antibodies , 2019, mBio.

[12]  M. Kiso,et al.  Antigenic drift originating from changes to the lateral surface of the neuraminidase head of influenza A virus , 2019, Nature Microbiology.

[13]  Iván Sanz,et al.  Heterotypic Neuraminidase Antibodies Against Different A(H1N1) Strains are Elicited after Seasonal Influenza Vaccination , 2019, Vaccines.

[14]  S. Bühler,et al.  Flucelvax Tetra: a surface antigen, inactivated, influenza vaccine prepared in cell cultures , 2019, ESMO Open.

[15]  David J. Topham,et al.  Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies , 2018, Cell.

[16]  A. Fauci,et al.  Chasing Seasonal Influenza - The Need for a Universal Influenza Vaccine. , 2018, The New England journal of medicine.

[17]  L. Grohskopf,et al.  Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2018–19 Influenza Season , 2015, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[18]  J. Powers,et al.  Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model , 2016, mBio.

[19]  M. Eichelberger,et al.  Comparative Efficacy of Monoclonal Antibodies That Bind to Different Epitopes of the 2009 Pandemic H1N1 Influenza Virus Neuraminidase , 2015, Journal of Virology.

[20]  M. Eichelberger,et al.  Optimization of an enzyme-linked lectin assay suitable for rapid antigenic characterization of the neuraminidase of human influenza A(H3N2) viruses. , 2015, Journal of virological methods.

[21]  P. Palese,et al.  Vaccination with Adjuvanted Recombinant Neuraminidase Induces Broad Heterologous, but Not Heterosubtypic, Cross-Protection against Influenza Virus Infection in Mice , 2015, mBio.

[22]  M. Eichelberger,et al.  Structural characterization of a protective epitope spanning A(H1N1)pdm09 influenza virus neuraminidase monomers , 2015, Nature Communications.

[23]  M. Eichelberger,et al.  An optimized enzyme-linked lectin assay to measure influenza A virus neuraminidase inhibition antibody titers in human sera. , 2014, Journal of virological methods.

[24]  D. Dou,et al.  The Influenza Virus Neuraminidase Protein Transmembrane and Head Domains Have Coevolved , 2014, Journal of Virology.

[25]  J. Belmont,et al.  Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase. , 2013, The Journal of infectious diseases.

[26]  D. Dou,et al.  Polar Residues and Their Positional Context Dictate the Transmembrane Domain Interactions of Influenza A Neuraminidases* , 2013, The Journal of Biological Chemistry.

[27]  I. Barr,et al.  Neuraminidase-Inhibiting Antibody Is a Correlate of Cross-Protection against Lethal H5N1 Influenza Virus in Ferrets Immunized with Seasonal Influenza Vaccine , 2013, Journal of Virology.

[28]  R. Daniels,et al.  Assembly of Subtype 1 Influenza Neuraminidase Is Driven by Both the Transmembrane and Head Domains* , 2012, The Journal of Biological Chemistry.

[29]  M. Eichelberger,et al.  Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice. , 2012, Virology.

[30]  Gavin J. D. Smith,et al.  Genetic evolution of the neuraminidase of influenza A (H3N2) viruses from 1968 to 2009 and its correspondence to haemagglutinin evolution. , 2012, The Journal of general virology.

[31]  I. Wilson,et al.  Influenza Virus Neuraminidases with Reduced Enzymatic Activity That Avidly Bind Sialic Acid Receptors , 2012, Journal of Virology.

[32]  The Coming Era of Quadrivalent Human Influenza Vaccines: Who will Benefit? , 2012, Drugs.

[33]  H. Ehrlich,et al.  A vero cell-derived whole-virus H5N1 vaccine effectively induces neuraminidase-inhibiting antibodies. , 2012, The Journal of infectious diseases.

[34]  Jianhua He,et al.  The 2009 pandemic H1N1 neuraminidase N1 lacks the 150-cavity in its active site , 2010, Nature Structural &Molecular Biology.

[35]  Chih-Jen Wei,et al.  Cross-Neutralization of 1918 and 2009 Influenza Viruses: Role of Glycans in Viral Evolution and Vaccine Design , 2010, Science Translational Medicine.

[36]  R. Couch,et al.  A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. , 2010, Vaccine.

[37]  M. Eichelberger,et al.  A miniaturized assay for influenza neuraminidase‐inhibiting antibodies utilizing reverse genetics‐derived antigens , 2009, Influenza and other respiratory viruses.

[38]  Ron A M Fouchier,et al.  Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses. , 2008, Vaccine.

[39]  Martin A. Nowak,et al.  Antibody neutralization and escape by HIV-1 , 2003, Nature.

[40]  T. Kurata,et al.  Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase. , 2000, Vaccine.

[41]  R. Webster,et al.  A DNA transfection system for generation of influenza A virus from eight plasmids. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[42]  E. D. Kilbourne,et al.  Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response. , 1998, Vaccine.

[43]  R. Webster,et al.  Measurement of anti-influenza neuraminidase antibody using a peroxidase-linked lectin and microtitre plates coated with natural substrates. , 1990, Journal of immunological methods.

[44]  K. Bergmann,et al.  The lectin neuraminidase inhibition test: a new method for the detection of antibodies to neuraminidase. , 1983, Journal of biological standardization.

[45]  K. Bergmann,et al.  Simple test for detection of virus neuraminidase and antineuraminidase using lectins (lectin-neuraminidase test system). , 1980, Zentralblatt fur Bakteriologie. 1. Abt. Originale. A: Medizinische Mikrobiologie, Infektionskrankheiten und Parasitologie.

[46]  R. Lotan,et al.  The purification, composition, and specificity of the anti-T lectin from peanut (Arachis hypogaea). , 1975, The Journal of biological chemistry.

[47]  A. S. Beare,et al.  The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses , 1972, Epidemiology and Infection.

[48]  R. Chanock,et al.  Association of serum anti-neuraminidase antibody with resistance to influenza in man. , 1972, The New England journal of medicine.

[49]  A. Kendal,et al.  Studies with avian influenza A viruses: cross protection experiments in chickens. , 1971, The Journal of general virology.

[50]  E. D. Kilbourne,et al.  Independent variation in nature of hemagglutinin and neuraminidase antigens of influenza virus: distinctiveness of hemagglutinin antigen of Hong Kong-68 virus. , 1969, Proceedings of the National Academy of Sciences of the United States of America.

[51]  E. D. Kilbourne,et al.  Protective Effects of Specific Immunity to Viral Neuraminidase on Influenza Virus Infection of Mice , 1968, Journal of virology.

[52]  T. Francis,et al.  Protective Effect of Vaccination Against Induced Influenza A.∗ , 1944, The Journal of clinical investigation.

[53]  T. Francis,et al.  Protective Effect of Vaccination Against Induced Influenza B.∗ , 1944 .